The PSA test is only one tool used to screen for early signs of prostate cancer. An elevated “PSA results should be correlated with the digital rectal examination” (Dains et al., 2016, p. 491). Ball et al., (2015), explain that the benefit of PSA screening far outweighs the associated harms which can include false-positives, unnecessary treatment, and unnecessary biopsies. References Adhyam, M., & Gupta, A. K. (2012). A Review on the clinical utility of PSA in cancer prostate. Indian Journal of Surgical Oncology, 3 (2), 120–129. - org.ezp.waldenulibrary.org/10.1007/s13193-012-0142-6 Ball, J. W., Dains, J. E., Flynn, J. A., Solomon, B. S., & Stewart, R. W. (2015). Seidel's guide to physical examination (8th ed.). St. Louis, MO: Elsevier Mosby. Dains, J. E., Baumann, L. C., & Scheibel, P. (2016). Advanced health assessment and clinical diagnosis in primary care (5th ed.). St. Louis, MO: Elsevier Mosby. Mayo Clinic (2018). PSA Test. Retrieved from - procedures/psa-test/about/pac-20384731 Okello, T. R., Alema, N. O., & Ogwang, D. M. (2014). Prostatic specific antigen (PSA) relationship to patients age, prostate volume and prostate histology at st mary's hospital 2
lacor. East & Central African Journal of Surgery, 19 (2), 87–96. Retrieved from rue&db=a9h&AN=109133939&site=eds-live&scope=site 3
You've reached the end of your free preview.
Want to read all 3 pages?